Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Advanced or Recurrent Endometrial Cancer

Fast replyRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying treatments for endometrial cancer, specifically a type known as proficient mismatch repair (pMMR) endometrial carcinoma. The study is investigating the effectiveness and safety of a combination treatment using sacituzumab tirumotecan and pembrolizumab, compared to using pembrolizumab alone. Sacituzumab tirumotecan is a medication that targets cancer cells, while pembrolizumab is an immunotherapy drug that helps the immune system fight cancer.

The purpose of the study is to compare these treatments to see which is more effective in maintaining the health of participants with advanced or recurrent endometrial cancer. Participants will receive either the combination of sacituzumab tirumotecan and pembrolizumab or pembrolizumab alone. The study will monitor the participants' health over time to assess the progression of the disease and overall survival rates.

Throughout the study, participants will be regularly evaluated to track their response to the treatment. This includes monitoring for any side effects and changes in their quality of life. The study aims to provide valuable information on the best treatment approach for individuals with this type of endometrial cancer.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, participants will be informed about the trial's purpose, procedures, and potential risks and benefits. Consent will be obtained to ensure understanding and agreement to participate.

  2. Step 2

    Initial assessment

    Participants will undergo an initial assessment to confirm eligibility. This includes a review of medical history and a physical examination. Imaging tests may be conducted to evaluate the current state of the endometrial cancer.

  3. Step 3

    Randomization

    Participants will be randomly assigned to one of two groups: one receiving sacituzumab tirumotecan in combination with pembrolizumab, and the other receiving pembrolizumab alone. This process ensures that the study results are unbiased.

  4. Step 4

    Treatment administration

    Participants will receive their assigned treatment. Pembrolizumab is administered as an intravenous infusion, which means it is given directly into a vein through a drip. The frequency and dosage will be determined by the study protocol and the healthcare team.

  5. Step 5

    Regular monitoring

    Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. This includes physical exams, blood tests, and imaging studies. The healthcare team will assess the cancer's response to the treatment and any side effects experienced.

  6. Step 6

    Completion of treatment

    Once the treatment phase is completed, participants will undergo a final assessment. This will include a comprehensive evaluation of their health status and the effectiveness of the treatment.

  7. Step 7

    Follow-up

    After completing the treatment, participants will enter a follow-up phase. This involves periodic visits to monitor long-term health outcomes and any delayed side effects. The follow-up period is crucial for gathering data on the treatment's long-term efficacy and safety.

Who can join the trial?

5 criteria

  • Must have a confirmed diagnosis of primary advanced or recurrent endometrial carcinoma that is proficient mismatch repair (pMMR). This means the cancer cells have a normal ability to repair DNA.
  • Must have disease that can be seen on imaging tests, with measurable Stage III or either measurable or non-measurable Stage IV or recurrent disease. This is determined by a set of guidelines called Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1).
  • Must not have received any prior systemic therapy for endometrial carcinoma, except in specific cases: one prior line of systemic platinum-based adjuvant and/or neoadjuvant chemotherapy (treatments given before or after the main treatment to help improve outcomes) in a curative setting, prior radiation with or without chemotherapy that helps radiation work better if it was more than 2 weeks before starting the study treatment, or prior hormonal therapy for endometrial carcinoma that was stopped at least 1 week before starting the study treatment.
  • Must be female.
  • Must be within the age range specified by the study, which typically includes adults.

Who cannot join the trial?

3 criteria

  • Participants must not have any other type of cancer besides pMMR endometrial carcinoma. This is a specific type of cancer affecting the lining of the uterus.
  • Participants cannot be male. Only females are eligible for this study.
  • Participants must not be part of a vulnerable population. This means they should not be in a situation that makes them more at risk or unable to give informed consent.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Sacituzumab Tirumotecan

    is a type of treatment that combines a drug with an antibody. The antibody part helps the drug find and attach to cancer cells. Once attached, the drug part works to kill the cancer cells. This treatment is being tested to see if it can help people with a specific type of endometrial cancer, which is a cancer that starts in the lining of the uterus.

  • Pembrolizumab

    is a medication that helps the body's immune system fight cancer. It works by blocking a specific protein on cancer cells, which allows the immune system to better recognize and attack these cells. This medication is already used to treat various types of cancer, and in this study, it is being tested to see how well it works as a maintenance treatment for endometrial cancer when used alone or in combination with another drug.

What is already known about the treatment

  • Sacituzumab Tirumotecan

    Sacituzumab Tirumotecan is administered through an intravenous infusion, meaning it is delivered directly into the bloodstream via a vein. It is currently being studied in clinical trials as a potential treatment for endometrial cancer that is proficient in mismatch repair (pMMR). The main therapeutic indication for this medication is as a maintenance treatment for advanced or recurrent endometrial carcinoma. At the molecular level, Sacituzumab Tirumotecan works by targeting and binding to specific proteins on cancer cells, delivering a toxic payload that helps to kill these cells. It is classified pharmacologically as an antibody-drug conjugate, which combines an antibody with a chemotherapy drug to specifically target cancer cells.

  • Pembrolizumab

    Pembrolizumab is administered through an intravenous infusion, allowing it to enter the bloodstream directly. It is a well-established medication in the field of oncology, particularly for treating various types of cancer, including endometrial cancer with proficient mismatch repair (pMMR). The main therapeutic indication for Pembrolizumab in this context is as a maintenance treatment for advanced or recurrent endometrial carcinoma. Its mechanism of action involves blocking a specific protein on immune cells, known as PD-1, which helps the immune system recognize and attack cancer cells more effectively. Pembrolizumab is classified as an immune checkpoint inhibitor, a type of immunotherapy that enhances the body's natural defenses against cancer.

Investigated diseases

Endometrial Carcinoma – Endometrial carcinoma is a type of cancer that begins in the lining of the uterus, known as the endometrium. It typically starts when cells in the endometrium undergo changes and begin to grow uncontrollably, forming a tumor. As the disease progresses, the cancerous cells can invade nearby tissues and organs, such as the cervix and ovaries. In advanced stages, the cancer may spread to distant parts of the body, including the lymph nodes, lungs, and liver. The progression of endometrial carcinoma can vary, with some cases remaining localized for extended periods, while others may advance more rapidly. The disease is often associated with symptoms such as abnormal vaginal bleeding, pelvic pain, and changes in menstrual cycles.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-519331-42-00Protocol codeMK-2870-033Estimated enrolment1 196 patientsSponsorMerck Sharp & Dohme LLC

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).